iBio and TheoremDx Collaborate to Develop Proteins for Rapid Diagnostics Testing Products
September 18 2017 - 8:00AM
iBio, Inc. (NYSE AMERICAN:IBIO) – iBio, with its subsidiary, iBio
CDMO LLC in Bryan/College Station, Texas ("iBio CDMO"), has
partnered with TheoremDx, Inc., in Edina, Minnesota, to develop
proteins for rapid diagnostic testing products.
The collaboration will leverage the TheoremDx
point-of-care diagnostic system and the protein development and
manufacturing capabilities of iBio. The goal of the collaboration
is to serve the citizens of the US and the world through the rapid
development and manufacturing of proprietary plant proteins for
point-of-care diagnostic testing products. The initial focus is on
developing rapid diagnostic tests to identify and distinguish
specific neglected tropical diseases (Zika, Dengue, Chikungunya,
and West Nile) from each other and to create a superior next
generation HIV test. Rapid and simultaneous testing for these
tropical diseases is desirable because they may present with
similar symptoms but require different therapies. iBio has already
delivered new proteins to TheoremDx for testing.
The iBio CDMO leadership team has worked with
TheoremDx over the last six months to generate new approaches for
engineering proteins to optimize TheoremDx’ proprietary diagnostic
system for the identification of multiple diseases and therapeutic
choices. iBio CDMO operates its large biotherapeutics manufacturing
facility in the Texas A & M Biocorridor.
Dr. Bruce Batten, Chief Scientific Officer of
TheoremDx, commented, “TheoremDx has leveraged the flexibility of
the iBio system to screen multiple candidate proteins to optimize
diagnostic capabilities in our system.”
Dr. Barry Holtz, President of iBio CDMO, stated,
“Our expression system delivers candidates quickly to TheoremDx and
our production system allows rapid, confident cGMP scale-up of
production. This collaboration meets the demands for rapid
establishment of new diagnostics.”
Both iBio and TheoremDx see the collaboration as
a major strategic step in advancing early rapid infectious disease
detection internationally and the crucial role it plays in
treatment and prevention strategies.
Primary leadership for the collaboration
includes Frank Kiesner (CEO, TheoremDx Inc.), Stephanie Griffin
(EVP, TheoremDx Inc.), Dr. Bruce Batten (CSO, TheoremDx Inc.),
Robert Erwin (President, iBio Inc.) and Dr. Barry Holtz (President,
iBio CDMO LLC).
About TheoremDx, Inc.
TheoremDx, Inc., is an in vitro diagnostics
company committed to innovating solutions that meet the global need
for rapid diagnostic testing for infectious disease, antibiotic
resistance, and healthcare-associated infections. The Company’s
THEO™ system leverages proprietary molecular identification and
susceptibility methods. The Company’s product pipeline is
focused on neglected tropical disease, HIV, bacterial ID and AST
testing.
About iBio, Inc.
iBio, a leader in developing plant-based
biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the
large-scale development and manufacturing facility of its
subsidiary iBio CDMO LLC in Bryan, Texas. The facility houses
laboratory and pilot-scale operations, as well as large-scale
automated hydroponic systems capable of growing over four million
plants as "in process inventory" and delivering over 300 kilograms
of therapeutic protein pharmaceutical active ingredient per year.
iBio applies its technology for the benefit of its clients and the
advancement of its own product interests. The Company’s pipeline is
comprised of proprietary candidates for the treatment of a range of
fibrotic diseases including idiopathic pulmonary fibrosis, systemic
sclerosis, and scleroderma. IBIO-CFB03, based on the Company's
proprietary gene expression technology, is the Company’s lead
therapeutic candidate being advanced for IND development.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
CONTACT:Stephanie CarringtonICR, Inc.
stephanie.carrington@icrinc.com646-277-1282
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024